Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America v. Bloss, et al
Case Number:
1:17-cv-11818
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
October 18, 2017
Judge Hesitant To Rubber-Stamp Aegerion's $36M Fraud Deal
A Massachusetts federal judge renewed his criticism Wednesday for plea bargains that deprive courts of sentencing discretion, but stopped short of tossing out a $36 million deal that would preclude him from weighing in on the ramifications of Aegerion Pharmaceuticals Inc. admitting to fraud in connection with its expensive cholesterol drug.
-
September 22, 2017
Aegerion To Pay $40M To End Host Of Juxtapid Claims
Massachusetts-based biopharmaceutical company Aegerion Pharmaceuticals Inc. agreed Friday to pay about $40 million to end criminal and civil allegations by the U.S. Department of Justice and fraud charges brought by the U.S. Securities and Exchange Commission over an expensive cholesterol treatment.